Baseline neutrophilia, derived neutrophil‐to‐lymphocyte ratio (dNLR), platelet‐to‐lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel
Nivolumab is a novel therapeutic option in NSCLC, associated with a significant survival gain compared with Docetaxel. However, predictive biomarkers are lacking. The presence of systemic inflammation has been correlated with poor outcome in many cancer types. We aimed to evaluate whether there is a...
Gespeichert in:
| Veröffentlicht in: | Journal of cellular physiology 2018-10, Vol.233 (10), p.6337-6343 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6343 |
|---|---|
| container_issue | 10 |
| container_start_page | 6337 |
| container_title | Journal of cellular physiology |
| container_volume | 233 |
| creator | Russo, Alessandro Franchina, Tindara Ricciardi, Giuseppina R.R. Battaglia, Alessandra Scimone, Antonino Berenato, Rosa Giordano, Antonio Adamo, Vincenzo |
| description | Nivolumab is a novel therapeutic option in NSCLC, associated with a significant survival gain compared with Docetaxel. However, predictive biomarkers are lacking. The presence of systemic inflammation has been correlated with poor outcome in many cancer types. We aimed to evaluate whether there is a correlation between some indicators of inflammation and response to Nivolumab or Docetaxel in pre‐treated NSCLCs. Data of 62 patients receiving Nivolumab or Docetaxel were analyzed. Baseline neutrophilia and thrombocytosis were not associated with response. High dNLR was associated with no response to Nivolumab, but not with Docetaxel, whereas high PLR correlated with low treatment response in both groups. Among refractory patients, a higher incidence of thrombocytosis, neutrophilia, high PLR, and high dNLR levels were observed compared with the overall population. This is one of the first reports in this field and suggests that indicators of inflammation might be included together with other predictive biomarkers in the baseline evaluation of patients candidate for immunotherapy.
We aimed to evaluate whether there is a correlation between some indicators of inflammation and response to Nivolumab or Docetaxel in pre‐treated NSCLCs. The results of this study suggest that indicators of inflammation such as baseline neutrophilia, thrombocytosis, and high dNLR are usually associated with a dismal prognosis and low efficacy of both chemotherapy and immunotherapy in NSCLC. Given their relative easy estimation, baseline evaluation of these indicators may be included together with other predictive biomarkers in the baseline evaluation of patients candidate for immunotherapy. |
| doi_str_mv | 10.1002/jcp.26609 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6767577</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2068378694</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4439-e56bb4a7a367d86ec54b10e4e314d7ff21f9883356d0466053921f0581a50dbb3</originalsourceid><addsrcrecordid>eNp1kc1u1DAQxy0EokvhwAsgS1y6UtM6sePEl0oQvrVaKj7OluPMdr1y7OA4W_bGI_BWvAdPgumWqhx6GUszP_08mj9CT3NykhNSnG70cFJwTsQ9NMuJqDLGy-I-mqVZnomS5Qfo0ThuCCFCUPoQHRSCV0XNxAz9eqlGsMYBdjDF4Ie1sUYd4w6C2UJ3q_v7x8_oU7G7flh7vYuAg4rG46Nuufg0P8aDVREsxLvB8ytOuQ77KWrfAzYOO-_w2CtrsYZU7OQusFZOQ8BHy8_NopnjGCCpO3xp4hovzdbbqVct9gG_8hqi-g72MXqwUnaEJ9fvIfr65vWX5l22-Pj2ffNikWnGqMig5G3LVKUor7qagy5ZmxNgQHPWVatVka9EXVNa8o6wdNGSitQiZZ2rknRtSw_R2d47TG0PnQYXg7JyCKZXYSe9MvL_iTNreeG3kle8KqsqCZ5fC4L_NsEY5cZPwaWdZUF4TauaC5ao-Z7SwY9jgNXNDzmRfzOXKXN5lXlin91e6Yb8F3ICTvfApbGwu9skPzTne-Uf8cq9TQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2068378694</pqid></control><display><type>article</type><title>Baseline neutrophilia, derived neutrophil‐to‐lymphocyte ratio (dNLR), platelet‐to‐lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Russo, Alessandro ; Franchina, Tindara ; Ricciardi, Giuseppina R.R. ; Battaglia, Alessandra ; Scimone, Antonino ; Berenato, Rosa ; Giordano, Antonio ; Adamo, Vincenzo</creator><creatorcontrib>Russo, Alessandro ; Franchina, Tindara ; Ricciardi, Giuseppina R.R. ; Battaglia, Alessandra ; Scimone, Antonino ; Berenato, Rosa ; Giordano, Antonio ; Adamo, Vincenzo</creatorcontrib><description>Nivolumab is a novel therapeutic option in NSCLC, associated with a significant survival gain compared with Docetaxel. However, predictive biomarkers are lacking. The presence of systemic inflammation has been correlated with poor outcome in many cancer types. We aimed to evaluate whether there is a correlation between some indicators of inflammation and response to Nivolumab or Docetaxel in pre‐treated NSCLCs. Data of 62 patients receiving Nivolumab or Docetaxel were analyzed. Baseline neutrophilia and thrombocytosis were not associated with response. High dNLR was associated with no response to Nivolumab, but not with Docetaxel, whereas high PLR correlated with low treatment response in both groups. Among refractory patients, a higher incidence of thrombocytosis, neutrophilia, high PLR, and high dNLR levels were observed compared with the overall population. This is one of the first reports in this field and suggests that indicators of inflammation might be included together with other predictive biomarkers in the baseline evaluation of patients candidate for immunotherapy.
We aimed to evaluate whether there is a correlation between some indicators of inflammation and response to Nivolumab or Docetaxel in pre‐treated NSCLCs. The results of this study suggest that indicators of inflammation such as baseline neutrophilia, thrombocytosis, and high dNLR are usually associated with a dismal prognosis and low efficacy of both chemotherapy and immunotherapy in NSCLC. Given their relative easy estimation, baseline evaluation of these indicators may be included together with other predictive biomarkers in the baseline evaluation of patients candidate for immunotherapy.</description><identifier>ISSN: 0021-9541</identifier><identifier>EISSN: 1097-4652</identifier><identifier>DOI: 10.1002/jcp.26609</identifier><identifier>PMID: 29672849</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adult ; Aged ; biomarker ; Biomarkers ; Biomarkers, Tumor - blood ; Blood Platelets - pathology ; Cancer ; Carcinoma, Non-Small-Cell Lung - blood ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - pathology ; Correlation ; Docetaxel - administration & dosage ; Docetaxel - adverse effects ; Drug-Related Side Effects and Adverse Reactions - blood ; Drug-Related Side Effects and Adverse Reactions - pathology ; Female ; Humans ; Immunotherapy ; Indicators ; Inflammation ; Inflammation - blood ; Inflammation - drug therapy ; Inflammation - pathology ; Lung cancer ; Lymphocytes ; Lymphocytes - pathology ; Male ; Middle Aged ; Monoclonal antibodies ; Neutrophilia ; Neutrophils - pathology ; neutrophil‐to‐lymphocyte ratio ; Nivolumab ; Nivolumab - administration & dosage ; Nivolumab - adverse effects ; Non-small cell lung carcinoma ; NSCLC ; Patients ; platelet‐to‐lymphocyte ratio ; Prognosis ; Rapid Communication ; Rapid Communications ; Targeted cancer therapy ; Thrombocytosis ; Treatment Outcome</subject><ispartof>Journal of cellular physiology, 2018-10, Vol.233 (10), p.6337-6343</ispartof><rights>2018 The Authors. Published by WileyPeriodicals, Inc.</rights><rights>2018 The Authors. Journal of Cellular Physiology Published by WileyPeriodicals, Inc.</rights><rights>2018. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2018 The Authors Journal of Cellular Physiology Published by Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4439-e56bb4a7a367d86ec54b10e4e314d7ff21f9883356d0466053921f0581a50dbb3</citedby><cites>FETCH-LOGICAL-c4439-e56bb4a7a367d86ec54b10e4e314d7ff21f9883356d0466053921f0581a50dbb3</cites><orcidid>0000-0003-2074-2418</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjcp.26609$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjcp.26609$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29672849$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Russo, Alessandro</creatorcontrib><creatorcontrib>Franchina, Tindara</creatorcontrib><creatorcontrib>Ricciardi, Giuseppina R.R.</creatorcontrib><creatorcontrib>Battaglia, Alessandra</creatorcontrib><creatorcontrib>Scimone, Antonino</creatorcontrib><creatorcontrib>Berenato, Rosa</creatorcontrib><creatorcontrib>Giordano, Antonio</creatorcontrib><creatorcontrib>Adamo, Vincenzo</creatorcontrib><title>Baseline neutrophilia, derived neutrophil‐to‐lymphocyte ratio (dNLR), platelet‐to‐lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel</title><title>Journal of cellular physiology</title><addtitle>J Cell Physiol</addtitle><description>Nivolumab is a novel therapeutic option in NSCLC, associated with a significant survival gain compared with Docetaxel. However, predictive biomarkers are lacking. The presence of systemic inflammation has been correlated with poor outcome in many cancer types. We aimed to evaluate whether there is a correlation between some indicators of inflammation and response to Nivolumab or Docetaxel in pre‐treated NSCLCs. Data of 62 patients receiving Nivolumab or Docetaxel were analyzed. Baseline neutrophilia and thrombocytosis were not associated with response. High dNLR was associated with no response to Nivolumab, but not with Docetaxel, whereas high PLR correlated with low treatment response in both groups. Among refractory patients, a higher incidence of thrombocytosis, neutrophilia, high PLR, and high dNLR levels were observed compared with the overall population. This is one of the first reports in this field and suggests that indicators of inflammation might be included together with other predictive biomarkers in the baseline evaluation of patients candidate for immunotherapy.
We aimed to evaluate whether there is a correlation between some indicators of inflammation and response to Nivolumab or Docetaxel in pre‐treated NSCLCs. The results of this study suggest that indicators of inflammation such as baseline neutrophilia, thrombocytosis, and high dNLR are usually associated with a dismal prognosis and low efficacy of both chemotherapy and immunotherapy in NSCLC. Given their relative easy estimation, baseline evaluation of these indicators may be included together with other predictive biomarkers in the baseline evaluation of patients candidate for immunotherapy.</description><subject>Adult</subject><subject>Aged</subject><subject>biomarker</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - blood</subject><subject>Blood Platelets - pathology</subject><subject>Cancer</subject><subject>Carcinoma, Non-Small-Cell Lung - blood</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Correlation</subject><subject>Docetaxel - administration & dosage</subject><subject>Docetaxel - adverse effects</subject><subject>Drug-Related Side Effects and Adverse Reactions - blood</subject><subject>Drug-Related Side Effects and Adverse Reactions - pathology</subject><subject>Female</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Indicators</subject><subject>Inflammation</subject><subject>Inflammation - blood</subject><subject>Inflammation - drug therapy</subject><subject>Inflammation - pathology</subject><subject>Lung cancer</subject><subject>Lymphocytes</subject><subject>Lymphocytes - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Neutrophilia</subject><subject>Neutrophils - pathology</subject><subject>neutrophil‐to‐lymphocyte ratio</subject><subject>Nivolumab</subject><subject>Nivolumab - administration & dosage</subject><subject>Nivolumab - adverse effects</subject><subject>Non-small cell lung carcinoma</subject><subject>NSCLC</subject><subject>Patients</subject><subject>platelet‐to‐lymphocyte ratio</subject><subject>Prognosis</subject><subject>Rapid Communication</subject><subject>Rapid Communications</subject><subject>Targeted cancer therapy</subject><subject>Thrombocytosis</subject><subject>Treatment Outcome</subject><issn>0021-9541</issn><issn>1097-4652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kc1u1DAQxy0EokvhwAsgS1y6UtM6sePEl0oQvrVaKj7OluPMdr1y7OA4W_bGI_BWvAdPgumWqhx6GUszP_08mj9CT3NykhNSnG70cFJwTsQ9NMuJqDLGy-I-mqVZnomS5Qfo0ThuCCFCUPoQHRSCV0XNxAz9eqlGsMYBdjDF4Ie1sUYd4w6C2UJ3q_v7x8_oU7G7flh7vYuAg4rG46Nuufg0P8aDVREsxLvB8ytOuQ77KWrfAzYOO-_w2CtrsYZU7OQusFZOQ8BHy8_NopnjGCCpO3xp4hovzdbbqVct9gG_8hqi-g72MXqwUnaEJ9fvIfr65vWX5l22-Pj2ffNikWnGqMig5G3LVKUor7qagy5ZmxNgQHPWVatVka9EXVNa8o6wdNGSitQiZZ2rknRtSw_R2d47TG0PnQYXg7JyCKZXYSe9MvL_iTNreeG3kle8KqsqCZ5fC4L_NsEY5cZPwaWdZUF4TauaC5ao-Z7SwY9jgNXNDzmRfzOXKXN5lXlin91e6Yb8F3ICTvfApbGwu9skPzTne-Uf8cq9TQ</recordid><startdate>201810</startdate><enddate>201810</enddate><creator>Russo, Alessandro</creator><creator>Franchina, Tindara</creator><creator>Ricciardi, Giuseppina R.R.</creator><creator>Battaglia, Alessandra</creator><creator>Scimone, Antonino</creator><creator>Berenato, Rosa</creator><creator>Giordano, Antonio</creator><creator>Adamo, Vincenzo</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2074-2418</orcidid></search><sort><creationdate>201810</creationdate><title>Baseline neutrophilia, derived neutrophil‐to‐lymphocyte ratio (dNLR), platelet‐to‐lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel</title><author>Russo, Alessandro ; Franchina, Tindara ; Ricciardi, Giuseppina R.R. ; Battaglia, Alessandra ; Scimone, Antonino ; Berenato, Rosa ; Giordano, Antonio ; Adamo, Vincenzo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4439-e56bb4a7a367d86ec54b10e4e314d7ff21f9883356d0466053921f0581a50dbb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Aged</topic><topic>biomarker</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - blood</topic><topic>Blood Platelets - pathology</topic><topic>Cancer</topic><topic>Carcinoma, Non-Small-Cell Lung - blood</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Correlation</topic><topic>Docetaxel - administration & dosage</topic><topic>Docetaxel - adverse effects</topic><topic>Drug-Related Side Effects and Adverse Reactions - blood</topic><topic>Drug-Related Side Effects and Adverse Reactions - pathology</topic><topic>Female</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Indicators</topic><topic>Inflammation</topic><topic>Inflammation - blood</topic><topic>Inflammation - drug therapy</topic><topic>Inflammation - pathology</topic><topic>Lung cancer</topic><topic>Lymphocytes</topic><topic>Lymphocytes - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Neutrophilia</topic><topic>Neutrophils - pathology</topic><topic>neutrophil‐to‐lymphocyte ratio</topic><topic>Nivolumab</topic><topic>Nivolumab - administration & dosage</topic><topic>Nivolumab - adverse effects</topic><topic>Non-small cell lung carcinoma</topic><topic>NSCLC</topic><topic>Patients</topic><topic>platelet‐to‐lymphocyte ratio</topic><topic>Prognosis</topic><topic>Rapid Communication</topic><topic>Rapid Communications</topic><topic>Targeted cancer therapy</topic><topic>Thrombocytosis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Russo, Alessandro</creatorcontrib><creatorcontrib>Franchina, Tindara</creatorcontrib><creatorcontrib>Ricciardi, Giuseppina R.R.</creatorcontrib><creatorcontrib>Battaglia, Alessandra</creatorcontrib><creatorcontrib>Scimone, Antonino</creatorcontrib><creatorcontrib>Berenato, Rosa</creatorcontrib><creatorcontrib>Giordano, Antonio</creatorcontrib><creatorcontrib>Adamo, Vincenzo</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of cellular physiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Russo, Alessandro</au><au>Franchina, Tindara</au><au>Ricciardi, Giuseppina R.R.</au><au>Battaglia, Alessandra</au><au>Scimone, Antonino</au><au>Berenato, Rosa</au><au>Giordano, Antonio</au><au>Adamo, Vincenzo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Baseline neutrophilia, derived neutrophil‐to‐lymphocyte ratio (dNLR), platelet‐to‐lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel</atitle><jtitle>Journal of cellular physiology</jtitle><addtitle>J Cell Physiol</addtitle><date>2018-10</date><risdate>2018</risdate><volume>233</volume><issue>10</issue><spage>6337</spage><epage>6343</epage><pages>6337-6343</pages><issn>0021-9541</issn><eissn>1097-4652</eissn><abstract>Nivolumab is a novel therapeutic option in NSCLC, associated with a significant survival gain compared with Docetaxel. However, predictive biomarkers are lacking. The presence of systemic inflammation has been correlated with poor outcome in many cancer types. We aimed to evaluate whether there is a correlation between some indicators of inflammation and response to Nivolumab or Docetaxel in pre‐treated NSCLCs. Data of 62 patients receiving Nivolumab or Docetaxel were analyzed. Baseline neutrophilia and thrombocytosis were not associated with response. High dNLR was associated with no response to Nivolumab, but not with Docetaxel, whereas high PLR correlated with low treatment response in both groups. Among refractory patients, a higher incidence of thrombocytosis, neutrophilia, high PLR, and high dNLR levels were observed compared with the overall population. This is one of the first reports in this field and suggests that indicators of inflammation might be included together with other predictive biomarkers in the baseline evaluation of patients candidate for immunotherapy.
We aimed to evaluate whether there is a correlation between some indicators of inflammation and response to Nivolumab or Docetaxel in pre‐treated NSCLCs. The results of this study suggest that indicators of inflammation such as baseline neutrophilia, thrombocytosis, and high dNLR are usually associated with a dismal prognosis and low efficacy of both chemotherapy and immunotherapy in NSCLC. Given their relative easy estimation, baseline evaluation of these indicators may be included together with other predictive biomarkers in the baseline evaluation of patients candidate for immunotherapy.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29672849</pmid><doi>10.1002/jcp.26609</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-2074-2418</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-9541 |
| ispartof | Journal of cellular physiology, 2018-10, Vol.233 (10), p.6337-6343 |
| issn | 0021-9541 1097-4652 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6767577 |
| source | MEDLINE; Wiley Journals |
| subjects | Adult Aged biomarker Biomarkers Biomarkers, Tumor - blood Blood Platelets - pathology Cancer Carcinoma, Non-Small-Cell Lung - blood Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Correlation Docetaxel - administration & dosage Docetaxel - adverse effects Drug-Related Side Effects and Adverse Reactions - blood Drug-Related Side Effects and Adverse Reactions - pathology Female Humans Immunotherapy Indicators Inflammation Inflammation - blood Inflammation - drug therapy Inflammation - pathology Lung cancer Lymphocytes Lymphocytes - pathology Male Middle Aged Monoclonal antibodies Neutrophilia Neutrophils - pathology neutrophil‐to‐lymphocyte ratio Nivolumab Nivolumab - administration & dosage Nivolumab - adverse effects Non-small cell lung carcinoma NSCLC Patients platelet‐to‐lymphocyte ratio Prognosis Rapid Communication Rapid Communications Targeted cancer therapy Thrombocytosis Treatment Outcome |
| title | Baseline neutrophilia, derived neutrophil‐to‐lymphocyte ratio (dNLR), platelet‐to‐lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T06%3A53%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Baseline%20neutrophilia,%20derived%20neutrophil%E2%80%90to%E2%80%90lymphocyte%20ratio%20(dNLR),%20platelet%E2%80%90to%E2%80%90lymphocyte%20ratio%20(PLR),%20and%20outcome%20in%20non%20small%20cell%20lung%20cancer%20(NSCLC)%20treated%20with%20Nivolumab%20or%20Docetaxel&rft.jtitle=Journal%20of%20cellular%20physiology&rft.au=Russo,%20Alessandro&rft.date=2018-10&rft.volume=233&rft.issue=10&rft.spage=6337&rft.epage=6343&rft.pages=6337-6343&rft.issn=0021-9541&rft.eissn=1097-4652&rft_id=info:doi/10.1002/jcp.26609&rft_dat=%3Cproquest_pubme%3E2068378694%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2068378694&rft_id=info:pmid/29672849&rfr_iscdi=true |